XML 123 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets and Goodwill
 12 Months Ended
Dec. 29, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill
Intangible Assets and Goodwill
At the end of 2019 and 2018, the gross and net amounts of intangible assets were:
(Dollars in Millions)
 
2019
 
2018
Intangible assets with definite lives:
 
 

 
 

Patents and trademarks — gross
 
$
36,634

 
35,194

Less accumulated amortization
 
13,154

 
9,784

Patents and trademarks — net
 
$
23,480

 
25,410

Customer relationships and other intangibles — gross
 
$
22,056

 
21,334

Less accumulated amortization
 
9,462

 
8,323

Customer relationships and other intangibles — net*
 
$
12,594

 
13,011

Intangible assets with indefinite lives:
 
 

 
 

Trademarks
 
$
6,922

 
6,937

Purchased in-process research and development(1)
 
4,647

 
2,253

Total intangible assets with indefinite lives
 
$
11,569

 
9,190

Total intangible assets — net
 
$
47,643

 
47,611


*The majority is comprised of customer relationships
(1) In the fiscal year 2019, the Company completed the acquisition of Auris Health, Inc. and recorded an in-process research and development intangible asset of $2.9 billion. Additionally, in the fiscal first quarter of 2019, the Company recorded an IPR&D impairment charge of $0.9 billion for the remaining intangible asset value related to the development program of AL-8176, an investigational drug for the treatment of Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV) acquired with the 2014 acquisition of Alios Biopharma Inc. The impairment charge was based on additional information, including clinical data, which became available and led to the Company's decision to abandon the development of AL-8176. A partial impairment charge of $0.8 billion was previously recorded in the fiscal third quarter 2018 related to the development program of AL-8176.










Goodwill as of December 29, 2019 and December 30, 2018, as allocated by segment of business, was as follows:
(Dollars in Millions)
 
Consumer
 
Pharmaceutical
 
Medical Devices
 
Total
Goodwill at December 31, 2017
 
$
8,875

 
9,109

 
13,922

 
31,906

Goodwill, related to acquisitions
 
168

 
51

 
184

 
403

Goodwill, related to divestitures
 
—

 
—

 
(1,348
)
(1) 
(1,348
)
Currency translation/other
 
(373
)
 
(97
)
 
(38
)
 
(508
)
Goodwill at December 30, 2018
 
$
8,670

 
9,063

 
12,720

 
30,453

Goodwill, related to acquisitions
 
1,188

 
75

 
2,018

 
3,281

Currency translation/other
 
(122
)
 
31

 
(4
)
 
(95
)
Goodwill at December 29, 2019
 
$
9,736

 
9,169

 
14,734

 
33,639



(1) Goodwill of $1.0 billion is related to the divestiture of the LifeScan business. Goodwill of $0.3 billion is related to the divestiture of the Advanced Sterilization Products business which closed in 2019, and was pending and classified as assets held for sale on the Consolidated Balance Sheet as of December 30, 2018.

The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable assets included in cost of products sold was $4.5 billion, $4.4 billion and $3.0 billion before tax, for the fiscal years ended December 29, 2019, December 30, 2018 and December 31, 2017, respectively. Intangible asset write-downs are included in Other (income) expense, net.

The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:
(Dollars in Millions)
 
 
 
 
 
 
2020
 
2021
 
2022
 
2023
 
2024
$4,500
 
4,300
 
4,100
 
4,100
 
4,000


See Note 20 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.